Payment overview · 2025
General Payments
$1,522.05
86 reported records · 15 companies
Healthcare provider profile · identity verified
Seeam Haque, MD
Allopathic & Osteopathic Physicians|Family Medicine · JAMAICA, NY · NPI 1487041554
Verified facts
What the public records show
CMS Open Payments records show Seeam Haque, MD received $1,522.05 in general payments during 2025 across 86 reported records.
Ardelyx, Inc. accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Xhance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Optinose US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xhance as an associated drug or biological on 10863 records involving 5058 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xhance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $317.53 | 20.9% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.35 | 13.9% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $166.83 | 11.0% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $157.07 | 10.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.00 | 6.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.98 | 5.7% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $85.77 | 5.6% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $72.74 | 4.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.83 | 4.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.13 | 4.5% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $57.70 | 3.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.46 | 3.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.57 | 2.7% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.65 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.44 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,522.05 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $317.53 | 23 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $212.35 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $212.35 | 11 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $166.83 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $157.07 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $86.98 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $86.98 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $85.77 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $72.74 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.83 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.13 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $68.59 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $68.59 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $57.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.99 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 44 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 163 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| Xhance xhance |
2025 | Xhance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
163 | 57 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| Optinose US, Inc. Exact reporting entity; no affiliate inference |
2025 | Xhance open payments reported associated product |
CMS Open Payments — General Payments 10863 supporting records · 5058 recipient NPIs · example record 1163252000 |
Xhance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 442 | 167 |
| Atorvastatin Calcium | Atorvastatin Calcium | 428 | 152 |
| Gabapentin | Gabapentin | 329 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 113 |
| Omeprazole | Omeprazole | 315 | 109 |
| Fluticasone Propionate | Fluticasone Propionate | 252 | 98 |
| Famotidine | Famotidine | 251 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 76 |
| Losartan Potassium | Losartan Potassium | 244 | 94 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 197 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 78 |
| Mirtazapine | Mirtazapine | 179 | 49 |
| Metformin Hcl | Metformin Hcl | 173 | 64 |
| Lisinopril | Lisinopril | 170 | 68 |
| Farxiga | Dapagliflozin Propanediol | 163 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 159 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 54 |
| Naproxen | Naproxen | 131 | 50 |
| Simvastatin | Simvastatin | 123 | 50 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 117 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 115 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 43 |
| Montelukast Sodium | Montelukast Sodium | 111 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 44 |
| Glipizide Er | Glipizide | 95 | 34 |
| Icosapent Ethyl | Icosapent Ethyl | 90 | 57 |
| Januvia | Sitagliptin Phosphate | 90 | 25 |
| Carvedilol | Carvedilol | 87 | 29 |
| Nifedipine Er | Nifedipine | 84 | 35 |
| Metformin Hcl Er | Metformin Hcl | 75 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 30 |
| Jardiance | Empagliflozin | 72 | 25 |
| Prednisone | Prednisone | 72 | 51 |
| Ozempic | Semaglutide | 71 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 27 |
| Diclofenac Sodium Er | Diclofenac Sodium | 70 | suppressed |
| Meloxicam | Meloxicam | 69 | 30 |
| Trulicity | Dulaglutide | 64 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 61 | 22 |
| Hydrocortisone | Hydrocortisone | 58 | 23 |
| Baclofen | Baclofen | 55 | 17 |
| Lidocaine | Lidocaine | 54 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 33 |
| Furosemide | Furosemide | 51 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 36 |
| Eliquis | Apixaban | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 44 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 43 | 20 |
| Fluocinonide | Fluocinonide | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 15 |
| Entresto | Sacubitril/Valsartan | 36 | 14 |
| Glimepiride | Glimepiride | 36 | 15 |
| Trazodone Hcl | Trazodone Hcl | 36 | 15 |
| Latanoprost | Latanoprost | 35 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 16 |
| Finasteride | Finasteride | 31 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 15 |
| Ranolazine Er | Ranolazine | 30 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | 11 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 11 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Procto-Med Hc | Hydrocortisone | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Clotrimazole | Clotrimazole | 25 | 12 |
| Colchicine | Colchicine | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Atenolol | Atenolol | 24 | 12 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 22 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | 12 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | 11 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Xhance | Fluticasone Propionate | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,522.05 · 86 records | Ardelyx, Inc. | ABRYSVO, ACCRUFER, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, IBSRELA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VERQUVO, VOQUEZNA, Xhance, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error